EGFR and metastatic colorectal cancer: For patients with wild-type RAS (OMIM 190070 for KRAS and 164790 for NRAS) or BRAF (OMIM 164757) metastatic colorectal cancer (mCRC), the findings of previous trials14,16 suggested that an EGFR-targeted drug may be the optimal maintenance therapy after induction chemotherapy in combination with the EGFR-targeted drug.